

1 **Computational Mechanisms of Neuroimaging Biomarkers Uncovered by**
2 **Multicenter Resting-State fMRI Connectivity Variation Profile**

3
4 Okito Yamashita^{1,2}, Ayumu Yamashita^{2,3}, Yuji Takahara², Yuki Sakai², Yasumasa
5 Okamoto⁴, Go Okada⁴, Masahiro Takamura^{4,5}, Motoaki Nakamura⁶, Takashi Itahashi⁶,
6 Takashi Hanakawa^{7,8}, Hiroki Togo^{7,14}, Yujiro Yoshihara⁹, Toshiya Murai⁹, Tomohisa
7 Okada¹⁰, Jin Narumoto¹¹, Hidehiko Takahashi^{12,13}, Haruto Takagishi¹⁵, Koichi Hosomi¹⁶,
8 Kiyoto Kasai^{17,18,19}, Naohiro Okada^{17,18}, Osamu Abe²⁰, Hiroshi Imamizu^{2,21}, Takuya
9 Hayashi^{22,23}, Shinsuke Koike^{18,19,24}, Saori C.Tanaka,^{2,25} Mitsuo Kawato^{1,2}, Brain/MINDS
10 Beyond Human Brain MRI Group

11
12 ¹ RIKEN Center for Advanced Intelligence Project, Tokyo, Japan

13 ² Brain Information Communication Research Laboratory Group, Advanced
14 Telecommunications Research Institutes International, Kyoto, Japan

15 ³ Graduate School of Information Science and Technology, The University of Tokyo,
16 Tokyo, Japan

17 ⁴ Department of Psychiatry and Neurosciences, Graduate School of Biomedical and
18 Health Science, Hiroshima University, Hiroshima, Japan

19 ⁵ Department of Neurology, Faculty of Medicine, Shimane University, Shimane, Japan

20 ⁶ Medical Institute of Developmental Disabilities Research, Showa University, Tokyo,
21 Japan

22 ⁷ Department of Integrated Neuroanatomy and Neuroimaging, Graduate School of
23 Medicine, Kyoto University, Kyoto, Japan

24 ⁸ Integrative Brain Imaging Center, National Center of Neurology and Psychiatry,
25 Tokyo, Japan

26 ⁹ Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto
27 Japan

28 ¹⁰ Human Brain Research Center, Graduate School of Medicine, Kyoto University,
29 Kyoto, Japan

30 ¹¹ Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural
31 University of Medicine, Kyoto, Japan

32 ¹² Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and
33 Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

34 ¹³ Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo,
35 Japan

36

- 37 ¹⁴ Department of Advanced Neuroimaging, Integrative Brain Imaging Center, National
38 Center of Neurology and Psychiatry, Tokyo, Japan
39 ¹⁵ Brain Science Institute, Tamagawa University, Tokyo, Japan
40 ¹⁶ Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka,
41 Japan
42 ¹⁷ Department of Neuropsychiatry, Graduate School of Medicine, The University of
43 Tokyo, Tokyo, Japan
44 ¹⁸ The International Research Center for Neurointelligence (WPI-IRCN), The
45 University of Tokyo Institutes for Advanced Study (UTIAS), Tokyo, Japan
46 ¹⁹ University of Tokyo Institute for Diversity & Adaptation of Human Mind
47 (UTIDAHM), Tokyo, Japan
48 ²⁰ Department of Radiology, Graduate School of Medicine, The University of Tokyo,
49 Tokyo, Japan
50 ²¹ Department of Psychology, Graduate School of Humanities and Sociology, The
51 University of Tokyo, Tokyo, Japan
52 ²² Laboratory for Brain Connectomics Imaging, RIKEN Center for Biosystems
53 Dynamics Research, Hyogo, Japan
54 ²³ Department of Brain Connectomics, Graduate School of Medicine, Kyoto University,
55 Kyoto, Japan
56 ²⁴ Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences,
57 The University of Tokyo, Tokyo, Japan
58 ²⁵ Division of Information Science, Nara Institute of Science and Technology, Nara,
59 Japan

60

61 **Corresponding author:** Oktio Yamashita

62

63 **Abstract**

64 Resting-state functional connectivity (rsFC) is increasingly used to develop biomarkers
65 for psychiatric disorders. Despite progress, development of the reliable and practical FC
66 biomarker remains an unmet goal, particularly one that is clinically predictive at the
67 individual level with generalizability, robustness, and accuracy. In this study, we propose
68 a new approach to profile each connectivity from diverse perspective, encompassing not
69 only disorder-related differences but also disorder-unrelated variations attributed to
70 individual difference, within-subject across-runs, imaging protocol, and scanner factors.
71 By leveraging over 1500 runs of 10-minute resting-state data from 84 traveling-subjects
72 across 29 sites and 900 participants of the case-control study with three psychiatric

73 disorders, the disorder-related and disorder-unrelated FC variations were estimated for
74 each individual FC. Using the FC profile information, we evaluated the effects of the
75 disorder-related and disorder-unrelated variations on the output of the multi-connectivity
76 biomarker trained with ensemble sparse classifiers and generalizable to the multicenter
77 data. Our analysis revealed hierarchical variations in individual functional connectivity,
78 ranging from within-subject across-run variations, individual differences, disease effects,
79 inter-scanner discrepancies, and protocol differences, which were drastically inverted by
80 the sparse machine-learning algorithm. We found this inversion mainly attributed to
81 suppression of both individual difference and within-subject across-runs variations
82 relative to the disorder-related difference by weighted-averaging of the selected FCs and
83 ensemble computing. This comprehensive approach will provide an analytical tool to
84 delineate future directions for developing reliable individual-level biomarkers.

85

86 **Introduction**

87 Mental disorders have become a serious social problem in recent years.
88 Epidemiological and economic analyses have indicated that their global impact is
89 substantial in terms of human health and social welfare¹. However, current diagnostic
90 methods, which are based on self-reported symptoms or those identified during medical
91 interviews, are insufficient for treatment optimization. Biomarkers based on genes, blood
92 analyses, and neuroimaging data could overcome these limitations².

93 Resting-state functional connectivity (rsFC) is one of the most promising approaches for
94 developing psychiatric disorder biomarkers³. This method assesses brain functional
95 network by quantifying coactivation of spontaneous fluctuations across brain regions
96 using a noninvasive brain measurement technique, usually functional magnetic resonance
97 imaging (fMRI)^{4,5}. Extensive research has highlighted the relevance of functional
98 connectivity (FC) in relation to individual characteristics⁶⁻⁹, task activities^{10,11}, brain
99 states¹², anatomical structure¹³ and neuronal signals¹⁴⁻¹⁶. Owing to its simplicity,
100 versatility, interpretability, and sensitivity to individual variations, the FC biomarker
101 shows great promise for objective diagnosis¹⁷⁻²⁰, personalized treatment selection^{21,22},
102 and neuromodulation target identification in psychiatry²³⁻²⁶.

103 Despite progress, development of the reliable and practical FC biomarker remains an
104 unmet goal, particularly one that is clinically predictive at the individual level with
105 generalizability, robustness, and accuracy²⁷⁻²⁹. Although altered functional connections
106 between patient groups and healthy controls have been identified³⁰⁻³³, the individual-level
107 classifications can be only achieved with the help of the machine-learning algorithms. In
108 our multicenter study, we successfully developed major depressive disorder (MDD),

109 schizophrenia (SCZ), and autism spectrum disorder (ASD) biomarkers using ensemble
110 sparse classifiers, which generalized well across data from various centers^{18–20} and
111 maintained consistent performance on new data (anterograde generalization)³⁴. However,
112 its discrimination ability evaluated with completely independent datasets, with areas
113 under the curve of 0.74, 0.82, and 0.66–0.81 for MDD, SCZ, and ASD, respectively, may
114 not yet meet high standards.

115 Two key obstacles must be overcome to develop a reliable and practical biomarker. First,
116 there is the issue of limited dataset sizes used in machine-learning training, which is
117 problematic given patient heterogeneity. Despite recognizing the value of multicenter
118 rsFC studies for gathering large-scale data and creating biomarkers practical with real-
119 world data^{28,35–37}, there is still an incomplete comprehensive and quantitative
120 understanding of the variability in FC across multiple centers. Second, we face a
121 knowledge gap regarding how machine-learning algorithms facilitate individual
122 classification and what factors limit achieving higher accuracy.

123 This study aimed to comprehensively and quantitatively evaluate the effects of various
124 factors on FC and machine-learning-based biomarker outputs to delineate future
125 directions for developing reliable individual-level biomarkers. We leveraged data from
126 two major decade-spanning Japanese projects, the Strategic Research Program for Brain
127 Sciences (SRPBS) (2012–2018) and Brain/Minds Beyond (BMB) (2018–2024). These
128 projects have been uniquely featured for their extensive data with the collection from
129 numerous traveling-subjects (84 participants) and approximately 10,000 participants
130 including several thousand patients with diverse psychiatric and neurological disorders
131 across multiple centers^{37,38}. This study analyzed approximately 2,400 runs of 10-minute
132 eyes-open resting-state fMRI data from the BMB and SRPBS traveling-subject datasets,
133 as well as an SRPBS multi-disorder dataset (Fig. 1). We found hierarchical variations in
134 individual FC, ranging from run-to-run variations, individual differences, disease effects,
135 inter-scanner discrepancies, and protocol differences. The sparse machine-learning
136 algorithm proposed in our previous study¹⁹ can effectively prioritize disease effects via
137 optimal selection of FCs, their weighting and ensemble averaging, and drastically
138 inverted the above order of variability factors. More specifically, we revealed three
139 distinct computational mechanisms that improve our biomarker's signal to noise ratio
140 (disorder effect/participant related variabilities) almost 15 times. These findings render
141 our rsFC biomarkers practical for clinical applications and highlight the need to further
142 minimize individual differences and within-subject run-to-run variability to improve
143 predictive modeling.

144

145 [Fig. 1]

146

147 **Results**

148 **FC variation analysis in the BMB traveling-subject dataset**

149 We applied a three-factor linear fixed effects model to the BMB traveling-subject dataset
150 to investigate FC variations due to participant, imaging protocol, and scanner factors and
151 unexplained residual components for each connection.

152 The magnitude distributions of the FC variations across all connections (71,631
153 connections using Glasser's Multimodal Parcellation (MMP) atlas) are presented in Fig.
154 2(a). The median values (5th–95th percentile) for the participant, protocol, and scanner
155 factors were 0.107 (0.066–0.192), 0.016 (0.004–0.042), and 0.0259 (0.012–0.055),
156 respectively; the magnitude of the median value of the unexplained residuals was larger
157 than that of the three factors (0.160 (0.146–0.183)). The distribution for the the participant
158 factor (individual differences) was broad, whereas the distributions for the protocol,
159 scanner, and residual factors were narrower.

160 To elucidate the origin of the FC variation attributed to unexplained residuals, we
161 investigated associations between it and within-subject across-run variations on the basis
162 of connectivity pattern similarity (i.e., the rank correlation between residual and within-
163 subject FC variation patterns). We observed a strong association between the residual and
164 within-subject FC variations (correlation coefficient: 0.71) (Fig. 2(b)). The median
165 magnitude of the within-subject FC variation was slightly smaller than that of the
166 residuals (0.138 vs 0.160, respectively), suggesting another unknown factor was
167 contributing to the residual components (Fig. 2(a)). This strong association (rank
168 correlation=0.57) was observed even when the data used to calculate the residual
169 component (595 runs, 42 participants) and within-subject (201 runs, 31 participants)
170 variations were completely separated (Supplementary Fig. 1), indicating a substantial
171 portion of the residual component effects could be accounted for by the within-subject
172 FC variation.

173 Subsequently, we examined brain regions and networks affected by each factor,
174 generating maps of the FC variations due to participant, protocol, and scanner factors and
175 within-subject variations and residual components. The imaging value for a specific brain
176 region was calculated as the average amplitude across all connections linking that specific
177 brain region to all others. The participant factor variation was large in regions associated
178 with the dorsal attention, frontoparietal, and default mode networks. The within-subject
179 variation was large over the whole brain, with larger variations in the somatosensory,
180 motor, and visual cortices, and certain dorsal attention network regions. Large protocol-

181 related variation was observed in the anterior and inferior parts of the brain, including the
182 orbitofrontal cortex, gyrus rectus, and olfactory regions. Large scanner-related variation
183 was observed in the superior frontal gyrus and cerebellum at the top and bottom of the
184 brain, respectively.

185 To characterize differences between two imaging protocols or scanners in the FC space,
186 we defined the distance between them as the mean absolute difference between the
187 corresponding estimated parameter vectors over all connections. We observed large
188 distances between the Harmonized Protocol (HARP) and SRPBS protocols and between
189 the SRPBS and Connectomes Related to Human Diseases (CRHD) protocols compared
190 with the distances between the HARP and CRHD protocols, as expected, as well as large
191 distances between the MR750W scanner from General Electric (GE) and the remaining
192 Siemens scanners (Supplementary Fig. 2(a)(b)).

193

194 [Fig. 2]

195

196 **FC variation analysis of the SRPBS traveling-subject dataset**

197 To assess commonalities and differences in the aforementioned findings, the same
198 analyses were applied to the SRPBS traveling-subject dataset using two-factor linear
199 fixed effects modeling with participant and scanner factors.

200 The distributions of the FC variation magnitudes across all connections (71,631
201 connections from Glasser's MMP atlas) and the association between residual component
202 and within-subject FC variations are presented in Fig. 3(a), (b). The median values and
203 quantiles of the participant and scanner factors were 0.080 (0.038–0.158) and 0.037
204 (0.019–0.071), respectively. The largest magnitude was observed for the residual
205 components (0.156 (0.138–0.189)). The distribution for the participant factor was broader
206 than that of the other factors. High connectivity pattern similarity was observed between
207 the residual and within-subject variations (correlation coefficient: 0.69), with the median
208 magnitude of the latter being smaller than that of the former (0.133 vs 0.160, respectively).
209 These results were consistent with those in the BMB traveling-subject dataset analysis
210 (Fig. 2(a), (b)).

211 Subsequently, we examined brain regions and networks affected by each factor. A trend
212 similar to that of the BMB dataset was observed, with some exceptions (Fig. 3(c), (d)).
213 The within-subject variation was large in terms of connectivity involving the cerebellum
214 and visual cortex, and large scanner-related variation was observed in the orbito-frontal
215 cortex. The pair-wise scanner distance matrix and dendrogram computed on the basis of
216 the agglomerative hierarchical clustering revealed that the Phillips Achieva and Siemens

217 scanners were similar; however, a larger separation was observed for the Signa and
218 MR750W scanners from GE and Siemens scanners (Supplementary Fig. 2(c)).

219

220 [Fig. 3]

221

222 **FC differences between neuropsychiatric disorder groups and healthy controls (HCs)**

223 We examined group-level FC differences between patients with MDD, ASD, or SCZ,
224 and HCs to compare the FC variations from the disorder-unrelated factors, e.g., imaging
225 protocol, scanner, participant, and within-subject variations.

226 The magnitude distributions of the FC differences for each disorder are shown in Fig.
227 4(a). The median values (5th–95th percentile) of the magnitudes for the MDD, ASD, and
228 SCZ groups were 0.019 (0.002–0.061), 0.020 (0.002–0.062), and 0.029 (0.003–0.086),
229 respectively, which were as small as the FC variations of the scanner and imaging protocol
230 factors. However, examining the upper tails of each distribution revealed substantial
231 effects for certain connections; more specifically, approximately 0.5%, 0.3%, and 2.3%
232 of all connections exhibited a magnitude exceeding 0.1 in the MDD, ASD, and SCZ
233 groups, respectively, highlighting the fact that accurate biomarker development requires
234 the selection of important disorder-specific connections. Furthermore, the comparatively
235 smaller FC differences in the MDD and ASD groups in comparison with that of the SCZ
236 group were indicative of the challenges associated with creating precise biomarkers for
237 MDD and ASD. The comparison of the disorder-related and disorder-unrelated FC
238 variations from the BMB traveling-subject dataset for the 50 largest disorder-related
239 connections (Supplementary Figs. 3–5) revealed that the magnitudes of the scanner and
240 imaging protocol factors were small for most connections, whereas those of the within-
241 subject and participant factors were as large as the disorder-related differences.

242 The brain regions and networks affected by each disorder are presented in Fig. 4(b), (c).
243 For all three, a large magnitude was observed for connectivity involving the thalamus.
244 For the MDD group, in addition to the thalamus, large FC differences were observed in
245 the somatosensory and motor regions, consistent with the results of a recent extensive
246 data analysis conducted by the PsyMRI consortium³²; however, this contradicts early
247 studies that emphasized default mode and front-parietal network involvement^{30,39}. For the
248 ASD group, large FC differences were observed for intra-network connections involving
249 somato-motor, ventral attention, subcortical, and visual networks. For the SCZ group,
250 large FC differences were observed in the thalamus and somatosensory and motor regions
251 in addition to changes in inter-network connections involving the ventral attention
252 network.

253

254 [Fig. 4]

255

256 Collectively, these results indicated that the impact of the scanner and imaging protocol
257 factors on biomarker development could be limited, whereas within-subject and
258 participant factors could have a greater impact and may require more careful
259 consideration.

260

261 **Signal-to-noise ratio (SNR) enhancement using multivariate connectivity**
262 **biomarkers**

263 We have shown that individual differences (participant factor) and within-subject
264 variations were as large as or even larger than the disorder-related differences at most
265 connections, highlighting the difficulty of developing reliable univariate connectivity
266 biomarkers that permit individual-level classification. However, previous studies
267 involving machine-learning algorithms have demonstrated that *multivariate* connectivity
268 biomarkers can facilitate individual-level classifications^{17,19,40}. To understand the factors
269 affecting such outputs, we investigated the impact of variations caused by disorder-
270 unrelated factors in the BMB traveling-subject data on the MDD, ASD, and SCZ
271 biomarkers we developed in a previous study using ensembles of least absolute shrinkage
272 and selection operator (LASSO) classifiers¹⁹. We hypothesized that machine-learning
273 algorithms could optimize connectivity weightings to empower the model to distinguish
274 patients from HCs, while suppressing the influence of individual differences within the
275 patients and HCs group.

276

277 [Fig. 5]

278

279 First, we investigated the connections selected by the LASSO algorithm using the
280 magnitude distributions of the FC variations. For comparison, we consider the naïve
281 greedy strategy in which the 50 largest disorder-related connections (see Supplementary
282 Figs. 3–5 for details of each individual FC) were selected and averaged. For the MDD
283 biomarker (Fig. 5(a)), the FC variation distributions of the top 50 LASSO-selected
284 connections (histogram left-half) were significantly different from those of the 50 largest
285 disorder-related connections (histogram right-half) with respect to the participant, within-
286 subject, scanner and disorder factors (two-sample Kolmogorov-Smirnov test, $p < 0.001$).
287 The LASSO algorithm did not limit its selection to the functional connections with the
288 50 largest differences between the disorder and HC groups; instead, it selected those with

289 smaller individual-, within-subject-, and scanner-related variations. Compared with the
290 magnitude distributions of all 71,631 FCs (violin plots), the distributions of the lasso-
291 selected FCs had the significantly different distribution only for the disorder factor (two-
292 sample Kolmogorov-Smirnov test, $p < 0.001$). On the other hand, the distributions of the
293 greedily selected FCs had the significant difference for the participant and within-subject
294 factors as well as the disorder factor (two-sample Kolmogorov-Smirnov test, $p < 0.001$).
295 Similar results were observed for the ASD and SCZ biomarkers, except for the lack of
296 significant differences in scanner-related FC variations (Fig. 5(b)(c)).

297 Subsequently, we evaluated the weighted linear summation-FC (WLS-FC) variations
298 caused by the disorder-unrelated and disorder-related factors to assess their impact on the
299 decision value of the diagnostic biomarkers. The WLS-FC variations for the MDD
300 biomarker are presented in Fig. 5(d); the mean variations of each individual classifier
301 output (shown by the unfilled bars) caused by the participant and within-subject factors
302 were less than half of the difference between the MDD and HC groups, whereas variations
303 caused by scanner and protocol factors were much smaller (approximately one-tenth of
304 that difference). Further reduction in WLS-FC variations was observed for the ensemble-
305 averaged output (filled bars), particularly for the participant and within-subject factors.
306 The same tendency was observed for the ASD and SCZ biomarkers (Fig. 5(e), (f),
307 respectively).

308 To quantify the signal improvement, we estimated the SNR of each FC or the classifier
309 output as the disorder-related difference divided by summation of the participants, within-
310 subject, scanner and imaging protocol variations (Fig. 6 and Supplementary Table 1). For
311 MDD, the distribution of the SNR estimates of each individual FC from all 71631 FCs
312 ranged from 3.8×10^{-7} to 0.48 with the median value 0.064. The average SNR of top
313 50 disorder-related FCs and top 50 LASSO-selected FCs were $0.365 (\pm 0.063)$ and 0.256
314 (± 0.095) , respectively. The SNR estimates of the LASSO classifier outputs before and
315 after ensemble average were $0.742 (\pm 0.132)$ and 0.965 , respectively. Thus, the ensemble
316 LASSO classifier improved the SNR by 15 times and 2.6 times compared with the median
317 SNR of whole 71631 FCs and the greedy univariate strategy. The similar values of the
318 signal improvement were observed for ASD and SCZ (ASD: 15.4 times and 3.1 times,
319 SCZ 13.9 times and 2.6 times). In summary, improvements of SNRs by the ensemble
320 LASSO biomarkers were achieved by the following three mechanisms: first, selecting
321 FCs with large disorder effects and modest participant or within-subject variability,
322 second, spatially weighted averaging of the selected FCs reduced the participants and
323 within-subject variations significantly, and third, the ensemble of 100 LASSO classifiers
324 further reduced the variations. We here roughly quantify contributions by the three factors

325 in improving the SNRs for the MDD. First, the top 50 LASSO-selected FCs have
326 $0.256/0.064=3.9$ times larger than the median SNR of whole 71,631 FCs. Second, the
327 linear weighted summation of the LASSO classifier improved $0.742/0.256=2.9$ times by
328 weighted spatial averaging; this is reminiscent of replacing spatial averaging by temporal
329 averaging based on Ergodic property in statistical physics, but the opposite in our case,
330 that is, replacing temporal averaging by spatial averaging. Third the ensemble averaging
331 improved $0.965/0.742=1.3$ times. Altogether, the entire procedure improved SNR by 15
332 times. This is in sharp contrast to SNRs close to but less than 1 for the 50 largest disorder-
333 related FCs. The ASD case is similar to MDD, and the SCZ case attains a little higher
334 SNR because of relatively larger disorder effects.

335

336 [Fig. 6]

337

338 These results supported our hypothesis that machine-learning algorithms could optimize
339 the connectivity weighting to maximize disorder-related differences while simultaneously
340 suppressing individual differences. Contrary to our expectations, we observed suppressed
341 within-subject variations as well.

342

343 **Discussion**

344 The present study involved a comprehensive and quantitative evaluation of the effects of
345 various factors on FC and machine learning-based biomarker outputs to delineate
346 directions for future research to establish reliable individual-level biomarkers. The
347 carefully-designed linear fixed modeling of the traveling-subject datasets revealed that
348 the effects of individual differences and residual components on FC variations were
349 several times greater than the variations caused by scanner and imaging protocol factors.
350 Additionally, the FC variations attributed to the residual components were highly similar
351 to the within-subject across-runs variations. Each factor affected brain regions and
352 networks differently; for example, large individual FC differences were observed in the
353 dorsal attention and front-parietal networks; large within-subject FC variations were
354 observed in the sensory and motor-related regions; and large scanner- and imaging
355 protocol-related FC variations were evident at the bottom and top of the brain. The
356 disorder-related FC difference was as small as the scanner- and imaging protocol-related
357 variation on average and was of similar magnitude to the individual FC differences and
358 within-subject FC variation at the connectivity with the largest disorder effects. By
359 evaluating the variations of the multi-connectivity biomarker outputs, we found a
360 reduction of the individual difference and within-subject variations by optimal weighting

361 of multiple connectivity and ensemble averaging. Our results revealed large variability in
362 disorder-unrelated factors at the level of single connections; however, the use of
363 multivariate connectivity biomarkers served as a noise-suppression mechanism,
364 increasing the SNR through optimal weighting and ensemble averaging. Furthermore,
365 this study was the first to evaluate FC variations related to specific imaging protocols and
366 their effects on biomarker outputs. All of our reported values for the FC variations were
367 based on Fisher's z-transformed Pearson correlation, enhancing interpretability across
368 studies. This approach differs from previous traveling-subject studies, offering a more
369 comprehensive understanding of FC variations and their implications on imaging
370 biomarker development^{35,36}.

371 The linear fixed effects modeling revealed that the FC variation caused by the participant
372 factor was several times larger than that caused by scanner and imaging protocol factors,
373 with even larger variation for the unexplained residual components. The distribution for
374 the participant variation was broad across connections, whereas the distributions for the
375 other three types of variations were narrower across both traveling-subject datasets, with
376 similar outcomes observed when the FC values were derived from volumed-based
377 anatomical parcellation (BrainVISA atlas, 137 regions without the cerebellum;
378 Supplementary Figs. 7 and 8). The larger contributions of the participant factor relative
379 to that of the other measurement factors were also consistent with findings of two
380 previous traveling-subject studies^{35,36}. This study was also the first to incorporate the
381 decomposition of measurement bias into the imaging protocol and scanner factors,
382 revealing slightly larger scanner-related FC variation than imaging protocol-related FC
383 variation. The larger impact of the participant factor in the BMB dataset compared with
384 that of the SRPBS dataset could be due to the wider variability in subject demographics
385 in the former dataset. For example, the SRPBS traveling-subject dataset included only
386 young, adult males, whereas the BMB dataset included both male and female adults in
387 their twenties to sixties.

388 The largest FC variations were associated with residual components that could not be
389 explained by the linear fixed effects model. The ratios of the unexplained residual
390 variations to the total variations averaged across all connections were 69% and 64% for
391 the SRPBS and BMB datasets, respectively, consistent with the 60–80% ratios attributed
392 to unexplained residual components in a previous study³⁵. However, the previous
393 traveling-subject studies did not investigate the residual components in detail. The present
394 study clearly showed the relevance of the residual components with the within-subject
395 variations by high connectivity pattern similarity between them (Fig. 2,3(a)). This result
396 remained unchanged when the data used for computing the residual components and

397 within-subjects variation were completely separated (Supplementary Fig. 9(a)). These
398 results suggested that the large proportions observed for the unexplained residual
399 components reflected the within-subject FC variation. It is important to note that the
400 within-subject variations here include variations across different days, as each
401 participant's data comprised at least two days of experiments, on average approximately
402 8 weeks apart, with three runs per day. The within-day variation for a participant can be
403 determined by subtracting the day-specific FC pattern, averaged over three runs, from
404 each run's data. We discovered that the within-participant within-day FC variation shared
405 a similar connectivity pattern with the current study's intra-participant inter-run FC
406 variation, albeit with a reduced magnitude (Supplementary Fig. 10).

407 The brain mapping of the participant, imaging protocol, scanner, and within-subject FC
408 variations revealed distinct patterns in the brain regions affected by each factor, with some
409 overlap. For example, the participant FC variations were large in regions associated with
410 the dorsal attention and frontoparietal networks, whereas the within-subject FC variation
411 was large in the somatosensory, motor, and visual cortices, as well as in certain regions
412 within the dorsal attention network. These distinct patterns were observed in both the
413 BMB and SRPBS datasets, with an exception being the large within-subject FC variation
414 observed in the cerebellum and visual cortex only in the SRPBS dataset. Similar distinct
415 patterns of between-subjects and within-subject FC variations have been reported in
416 several previous studies^{41,42}. Large imaging protocol- and scanner-related FC variations
417 were predominantly observed on the top and bottom of the brain, although the detailed
418 patterns slightly differed for each factor. A large imaging protocol FC variation was
419 observed in the anterior and inferior parts of the brain, including the orbitofrontal cortex,
420 gyrus rectus, and olfactory regions, whereas large scanner-related FC variation was
421 observed in the superior frontal gyrus and cerebellum; the latter FC variations were also
422 high in the anterior frontal parts of the brain for the SRPBS dataset, resembling the
423 scanner differences reported previously³⁵.

424 The comparison of the FC variations between the disorder-related factor and the
425 participant, within-subject, scanner, and imaging protocol factors (Fig. 4 and
426 Supplementary Figs. 3–5, 11) has particularly important implications for psychiatric
427 biomarker development. First, a small subset of connections exhibited substantial group
428 differences between patients and HCs. For example, the number and magnitude of
429 functional connections relevant to MDD and ASD were comparatively smaller than those
430 relevant to SCZ, suggesting that developing accurate MDD and ASD biomarkers might
431 be more challenging. Second, the disorder-related FC differences were comparable to or
432 smaller than the individual difference and within-subject variations, even when focusing

433 on 50 connections with the largest disorder-related differences (Supplementary Figs. 3–
434 5). Aggregating multiple connectivity changes is essential to allow for differentiating
435 patients from HCs at an individual level. Third, the magnitude of the imaging protocol-
436 related FC variations was small for most of the MDD-, ASD-, and SCZ-related
437 connections, except for several MDD-related connections around the somatosensory and
438 motor regions. Thus, imaging protocol-related FC differences may have a limited impact
439 on biomarker development. This finding is particularly important because it suggests
440 possibility of integrating two data sets from two distinct nationwide projects SRPBS and
441 BMB, enabling machine-learning-based biomarker development using combined datasets
442 comprising approximately 10,000 samples.

443 The investigation of the effect of disorder-unrelated variations on the multi-connectivity
444 biomarker outputs that we previously developed using the ensemble LASSO algorithm
445 revealed that individual difference and within-subject FC variations could be reduced by
446 optimal weighting of automatically selected FCs and ensemble averaging. The reduced
447 effect attributed to individual differences was expected, as the machine-learning
448 algorithm attempts to reduce within-group variance while simultaneously increasing the
449 between-group variance (i.e., differences between disorder and HC groups). However, the
450 reduced impact of the within-subject variation was surprising because there was no
451 explicit source of information about the such variation that the machine-learning
452 algorithm could have used in the training data, that is, no multiple scans from individual
453 participants were included in the discovery cohort for the biomarker development;
454 however, this effect might have been because the within-subject variations had some
455 commonality across subjects. Even though the individual difference and within-subject
456 variations were reduced, the magnitude of these two factors was larger than that of the
457 scanner and imaging protocol variations. This observation underscores the challenge of
458 further reducing the influence of individual differences and within-participant variations
459 to create even more robust and precise biomarkers, which is especially critical for
460 precision medicine applications. Addressing this challenge will require innovative
461 experimental and analytical approaches in future research endeavors. One possible
462 progression involves integrating the SRPBS and BMB datasets to form big datasets for
463 biomarker discovery. The expanded dataset size would allow for an increase in the
464 number of the selected FCs by the ensemble sparse classifiers. This increased number of
465 FCs would boost the SNR in distinguishing disease effects from irrelevant variations,
466 resulting in biomarkers that are more reliable, generalizable, precise, and applicable.

467 This study had several limitations. First, the use of the statistical model for factor
468 decomposition is limited to linear modeling with only a few factors. Although it may be

469 desirable to include non-linear effects, such as interactions between imaging protocols
470 and scanner types or to include other factors, such inclusion complicates the explanatory
471 matrix, resulting in the null space being impossible to interpret. Despite our efforts to
472 account for data variance with known factors, substantial portions remained unexplained.
473 Second, the SNR values in Fig. 6 and Supplementary Table 1 were only rough estimates.
474 We assumed the four disorder-unrelated factors as noise as well as independence among
475 the four factors. In addition, our estimates of signal could be overestimated because the
476 same dataset was used for both developing the classifiers and evaluating disorder-related
477 differences of the biomarker outputs. However, this overestimation is not expected to
478 affect the SNR comparison between the LASSO biomarkers and the top 50 disorder-
479 related FCs. Third, our analysis was based on 10-minute rsFC trials. The experiment
480 duration significantly affects the test-retest reliability of rsFC^{42,43}, so the extent of within-
481 participant variation should decrease with longer trial durations. Forth, we did not
482 implement a preprocessing pipeline specifically optimized for the HARP and CRHD
483 protocols. More sophisticated preprocessing techniques^{38,44}, which have been proposed
484 for data acquired with these protocols, could further improve biomarker performance. The
485 impact of preprocessing on FC variations should be explored in future studies.

486 In conclusion, this study provided comprehensive and quantitative understanding of the
487 effects of various factors on FC and machine-learning-based biomarker outputs. Our
488 study also demonstrates the benefit of characterizing each FC variation from diverse
489 perspectives, encompassing not only disorder-related differences but also disorder-
490 unrelated variations, e.g., those attributed to participant, within-subject, imaging protocol,
491 and scanner factors. This comprehensive approach is instrumental in advancing the
492 development of more robust, generalizable, and accurate biomarkers.

493

494 **Methods**

495 **Datasets**

496 This study analyzed two traveling-subject datasets derived from two national-wide
497 projects conducted in Japan (SRPBS, 2012–2018 and BMB, 2018–2023), as well as a
498 portion of the SRPBS multi-disorder dataset. The SRPBS project was the pioneering
499 multicenter study conducted to develop multicenter generalizable psychiatric biomarkers
500 using a unified imaging protocol. The subsequent BMB project aimed to improve
501 biomarker selection using a cutting-edge imaging protocol and data processing techniques.
502 To bridge the biomarker selection between two projects, the BMB traveling-subject data
503 were acquired using the SRPBS imaging protocol and two new imaging protocols.
504 Investigating the effects of these imaging protocols on FC variability was one of the

505 focuses of the present study.

506 A comprehensive description of the SRPBS traveling-subject and multi-disorder datasets
507 was provided in our previous study³⁷. All of SRPBS data used for the analysis is publicly
508 available. To summarize, nine young adult male subjects (age range: 24–32 years; mean
509 age: 27 ± 2.6 years) visited 12 sites in the traveling-subject dataset, participating in fMRI
510 experiments involving two or three runs of 10-minute resting-state testing within a single
511 experimental session at each site, resulting in the acquisition of 411 runs of 10-minute
512 eyes-open resting-state fMRI data. We employed a unified imaging protocol referred to
513 as the SRPBS protocol. Owing to hardware limitations, two phase-encoding directions
514 were used depending on the scanners used, either A->P (anterior to posterior) or P->A
515 (posterior to anterior). However, we did not differentiate the phase-encoding direction as
516 different imaging protocols because we corrected for the impact using the corresponding
517 field maps. The dataset included data collected from seven types of scanners from three
518 different MRI manufacturers (Siemens, GE, and Phillips). The SRPBS multi-disorder
519 dataset used for the analysis consisted of data from approximately 900 subjects, acquired
520 using the SRPBS imaging protocol at the following four sites. The dataset included data
521 from patients with three psychiatric disorders (MDD, ASD, and SCZ) and HCs (see
522 Supplementary Figs. 12 and 13 for graphical representations of the data).

523 Specific details pertaining to the BMB dataset were described in our previous study³⁸.
524 Briefly the data were derived from 75 subjects (48 males and 27 females; mean age:
525 31.8 ± 10.0 years) from 17 sites. Each subject had visited three or more sites, including
526 one of three hub sites according to a hub-and-spoke model, which differed from the
527 SRPBS traveling-subject design in which all subjects visited all sites. For each participant,
528 data were collected from at least two runs of a 10-minute eyes-open resting-state fMRI
529 task conducted in a single experimental session at each site. At least five healthy
530 participants were recruited at each site. In total, approximately 1,200 runs of 10-minute
531 eyes-open resting-state fMRI data were obtained using three imaging protocols, including
532 the SRPBS protocol previously mentioned, the CRHD protocol, which is the MRI
533 protocol developed by the CRHD initiative of the Human Connectome Project (HCP) in
534 the United States of America (USA), customized for high-performance, 3T MRI scanners
535 such as the MAGNETOM Prisma (Siemens Healthcare GmbH, Erlangen, Germany), and
536 the HARP, which is an HCP-style protocol with a short scanning time optimized for
537 clinical studies so that it can be used for multiple MRI scanners/sites and was designed
538 to obtain high-quality, standardized brain MRI data in a ‘clinically’ practical time window
539 (see Supplementary Table 2 for more details). Seven scanner types from two MRI
540 manufacturers (Siemens and GE) were included (see Supplementary Fig. 14 for a

541 graphical representation of the data).

542 All participants in all datasets provided written informed consent, and all recruitment
543 procedures and experimental protocols were approved by the institutional review boards
544 of the principal investigators' respective institutions.

545

546 **FC computation**

547 We computed a region-level whole-brain FC matrix using identical processing steps for
548 both the SRPBS and BMB datasets.

549 The resting-state fMRI images underwent preprocessing using the standard pipeline
550 implemented in fMRIPrep 1.0.8,⁴⁵ which consisted of several steps, including the
551 exclusion of the initial 10 seconds of data for T1 equilibration, slice-timing correction,
552 realignment, coregistration, distortion correction using a field map, segmentation of T1-
553 weighted structural images, normalization to the Montreal Neurological Institute space,
554 and surface projection.

555 Subsequently, the resting-state fMRI timeseries data underwent the following processing
556 steps: physiological noise removal by employing 12 regressors, which consisted of six
557 head motion parameters, signal averaging across the entire brain, and five anatomical
558 component-based noise correction (CompCor) components. The data were then
559 bandpass-filtered using a second-order Butterworth filter with a passband ranging from
560 0.01 to 0.08 Hz. Additionally, image volumes affected by head motion, as indicated by a
561 frame displacement exceeding 0.5 mm⁴⁶, were eliminated from further analysis, as were
562 runs with excessive head motion. A region-level whole-brain connectivity matrix was
563 computed using Glasser's surface-based MMP atlas; this consisted of 379 regions of
564 interest (ROIs) (360 cortical parcels and 19 subcortical parcels)⁴⁴ using the ciftify toolbox
565 version 2.0.2–2.0.3. The region timeseries was obtained by averaging the voxel timeseries
566 within each region. The connectivity matrix was obtained by calculating the Pearson
567 correlations between all regional timeseries pairs. Since the connectivity matrix is
568 symmetric, the lower triangular elements were extracted, and a vector was formed with a
569 size of 71,631×1 (referred to as a connectivity vector). Finally, Fisher's z-transformation
570 was applied to each element of the connectivity vector.

571 After excluding any data affected by image processing errors, excessive head motion,
572 and an insufficient number of runs at a single site from further analysis, we analyzed the
573 connectivity vectors from a total of 398 runs from 12 sites, including nine subjects, one
574 protocol and seven scanner types in the SRPBS traveling-subject dataset, and the
575 connectivity vectors from a total of 1,167 runs from 14 sites, including 73 subjects, three
576 protocols, and six scanner types in the BMB traveling-subject dataset (see Supplementary

577 Tables 3 and 4 for more details).

578

579 **Estimation of FC variations due to experimental factors**

580 To determine the influence of experimental factors such as the participant, scanner, or
581 imaging protocol on FC, we used a linear fixed effects model for each connection, which
582 allowed us to estimate the magnitude of these factors' effects. We used a three-factor
583 model consisting of the participant, scanner, and imaging protocol for the BMB traveling-
584 subject data, whereas a two-factor model consisting of the participant and scanner factors
585 was used for the SRPBS traveling-subject data.

586 We let z_{nc} be a z-transformed connectivity strength for a specific run indexed by n
587 and a connection indexed by c (N : total number of runs, C : total number of connections)

588 and let $\mathbf{z}_c = (z_{1c}, z_{2c}, \dots, z_{Nc})^T$ be a column vector containing all the strength for
589 connection c across all runs. Then, in the case of the three-factor model, we assumed a
590 linear regression model with three explanatory variables was represented as,

$$591 \mathbf{z}_c = X_p \boldsymbol{\beta}_c^p + X_{prot} \boldsymbol{\beta}_c^{prot} + X_{scan} \boldsymbol{\beta}_c^{scan} + \boldsymbol{\epsilon}_c \quad \dots (1).$$

592 Here, three factors are categorical values represented by the binary matrices
593 X_p, X_{prot} and X_{scan} , respectively. For example, the participant-factor matrix X_p would
594 be a matrix of size N -by- P (with P being the total number of participants) and the ij th
595 element would be 1 if the participant indexed by i participated in a run indexed by j ;
596 otherwise, it would be 0. The parameter vector $\boldsymbol{\beta}_c^p$ was a vector of size P -by-1 whose
597 element represents the magnitude for each participant. The explanatory matrices and the
598 parameter vectors for the protocol and scanner factors were defined in the same way. The
599 term $\boldsymbol{\epsilon}_c$ represented residuals that cannot be explained by the linear summation of three
600 factors.

601 The equation (1) can be rewritten in the simplified form

$$602 \mathbf{z}_c = \mathbf{X} \boldsymbol{\beta}_c + \boldsymbol{\epsilon}_c \quad \dots (2)$$

603 where $\mathbf{X} = [X_p \quad X_{prot} \quad X_{scan}]$ and $\boldsymbol{\beta}_c = [\boldsymbol{\beta}_c^{pt} \quad \boldsymbol{\beta}_c^{prot} \quad \boldsymbol{\beta}_c^{scant}]^t$ are a matrix and
604 vector concatenating three factors, respectively. Using the least squares method, the
605 parameter vector $\boldsymbol{\beta}_c$ could be obtained by solving the following normal equation,

$$606 \mathbf{X}^t \mathbf{X} \boldsymbol{\beta}_c = \mathbf{X}^t \mathbf{z}_c \quad \dots (3).$$

607 Since all three factors were categorical variables, the concatenated explanatory matrix \mathbf{X}
608 was not of full rank, which could be easily confirmed by summing the columns of
609 X_p, X_{prot} and X_{scan} , where all results would be a vector consisting of all ones. Thus, the
610 linear equation (3) did not have a unique solution (and the inverse of $\mathbf{X}^t \mathbf{X}$ does not exist),

611 but the least squares solution could be obtained using the Moore-Penrose generalized
612 inverse matrix,⁴⁷

$$613 \beta_c = (X^t X)^+ X^t z_c \dots (4).$$

614 This was the solution of the linear system (3) in which the minimum L2-norm and the
615 null space of $X^t X$ could be determined from the design of the explanatory matrix. The
616 singular value decomposition of the explanatory matrix provided information about the
617 null space. Thus, in our three-factor or two-factor model, we confirmed that the
618 undetermined components were constant values within each factor (see Supplementary
619 Fig. 9 for more details). Thus, the baseline values of each factor were arbitrary, and only
620 the differential values within each factor were meaningful.

621

622 **Quantification of FC variations due to experimental factors**

623 We computed the FC variations attributed to the participant (or individual subject),
624 protocol, and scanner factors by determining the standard deviation of
625 β_c^p , β_c^{prot} , and β_c^{scan} across the members within each factor, respectively. The residual
626 FC variation was obtained as the standard deviation of ϵ_c . The pair-wise distance matrix
627 between members of the scanner type and imaging protocol factors was computed by
628 calculating the mean absolute difference between corresponding estimated parameters
629 across all connections.

630

631 **Computation of within-subject across-runs FC variations**

632 To investigate the origin of residual FC variations resulting from the linear fixed effects
633 modeling, we computed within-subject across-runs FC variations directly from the FC
634 vectors. The within-subject FC variation is typically defined by the variability of
635 connectivity patterns between different runs within one subject. In this study, the within-
636 subject FC variations averaged over screened subjects were defined as follows. First, we
637 screened for subjects who had performed at least six runs under a single measurement
638 condition, such as the same site, protocol, or scanner, to estimate the subject-specific
639 within-subject FC variations robustly. For each chosen subject, the data were collected
640 from at least two days of experimental sessions, with three runs per day, and the subject-
641 specific within-subject FC variations were obtained by determining the connectivity-wise
642 standard deviation of the connectivity vectors across runs for that particular subject. Then,
643 the subject-average within-subject FC variations, which we simply referred to as the
644 within-subject FC variations in this study, were computed as the average of all subject-
645 specific within-subject FC variations.

646 After screening subjects with at least six runs under a single measurement condition,

647 the SRPBS dataset contained 132 runs from nine subjects acquired using a Trio scanner
648 at a single site named ATR, whereas the BMB dataset contained 201 runs from 31 subjects
649 acquired with the HARP and four different scanner types across seven sites.

650

651 **Computation of disorder-related FC variations**

652 For clinical applications, it is crucial to compare the FC differences associated with
653 neuropsychiatric disorders with those that are unrelated to the disorder, such as those
654 associated with the imaging protocol or scanner, or within-subject and participant FC
655 variations identified in the traveling-subject data analysis. Therefore, we computed the
656 disorder-related FC differences of three psychiatric disorders, including MDD, ASD, and
657 SCZ, using a portion of the data from the SRPBS multi-disorder dataset. The whole-brain
658 FC matrices were computed using Glasser's MMP atlas in the exact same way as for the
659 traveling-subject datasets. The statistical harmonization using the SRPBS traveling-
660 subject data was applied to reduce the site effects³⁰. For each psychiatric disorder, we
661 randomly selected HC subjects from the dataset for age-, sex-, and site-matching as much
662 as possible, with 138 patients with MDD and 138 HCs (age: $42.12 \pm$
663 12.33 and 41.76 ± 12.39 years, respectively; male ratios: 0.46, 0.54); 109 patients
664 with ASD and 109 HCs (age: 29.14 ± 8.35 and 31.25 ± 7.33 years, respectively;
665 male ratios: 0.84, 0.87), and 84 patients with SCZ and 84 HCs (age: $37.20 \pm$
666 11.24 and 37.18 ± 11.46 years, respectively; male ratios: 0.58, 0.57). The disorder-
667 related FC differences were computed as the absolute value of the group-averaged FC
668 difference between the patient and matched HC groups for each disorder.

669

670 **Analysis of the FC variations on multivariate connectivity biomarker outputs**

671 To understand the underlying mechanism behind the effectiveness of the multivariate
672 connectivity biomarkers on individual-level classifications, we analyzed the variations
673 attributed to the disorder-unrelated and disorder-related factors on the biomarker
674 outcomes. More specifically, we evaluated the variations attributed to the participant,
675 imaging protocol, scanner, and within-subject variation from the BMB traveling-subject
676 dataset and disorder factors from the SRPBS multi-disorder dataset using the weight
677 parameters of MDD, ASD, and SCZ biomarkers we identified previously¹⁹. The
678 biomarker of each psychiatric disorder consisted of an ensemble of 100 linear classifiers,
679 each of which was trained using partially overlapping but distinct subsampled data using
680 the least absolute shrinkage and selection operator (LASSO) algorithm and FC vectors
681 computed with the MMP atlas. The output of each classifier was a scalar value that
682 indicated the likelihood of the presence of the disorder, with the final decision value

683 obtained by averaging the outputs of all 100 classifiers. To clarify, if we denote the weight
684 parameter of the n -th classifier by \mathbf{w}_n and the FC vector of a subject by \mathbf{x} , then the final
685 decision value was calculated as $d = \frac{1}{100} \sum_{n=1}^{100} d_n$, where $d_n = \mathbf{w}_n^t \mathbf{x}$ represents the
686 decision value of each individual classifier. Thus, each classifier output is a WLS of
687 multiple FC values, which was referred to as the WLS-FC.

688 First, we investigated the FCs selected by the LASSO algorithm using the magnitude
689 distributions of the FC variations to assess the feature selection preferences of the
690 machine-learning algorithm. Given that the LASSO algorithm performs the feature
691 selection during the optimization of the parameter weighting, we focused on the
692 frequently selected FCs among the 100 classifiers and chose the top 50 most frequently
693 selected FCs on the basis of the average numbers of FCs selected for the MDD, ASD, and
694 SCZ biomarkers (49, 54.2, and 53.7, respectively). For comparison, we conducted two-
695 sample Kolmogorov-Smirnov testing between the FC variation distributions consisting
696 of the LASSO-selected connections and those consisting of the 50 largest disorder-related
697 connections (Fig. 5(d)).

698 Second, we analyzed the WLS-FC variations (i.e., variations of the biomarker outcomes)
699 attributed to the participant, scanner, imaging protocol, within-subject, and psychiatric
700 disorder factors, which were calculated for the output of each individual classifier and the
701 output after ensemble averaging. To compute the WLS-FC variation associated with a
702 particular factor, we required the FC deviation vector for each member of the factor. Each
703 element of the FC deviation vector was defined by a signed scalar value representing the
704 deviation from the mean across the members of the factor. For example, the FC deviations
705 of the participant factor were computed by subtracting participant-averaged beta
706 estimates from each participant for each FC. The imaging protocol- and scanner-related
707 FC deviations were computed in the same way. The disorder-related FC deviation was
708 computed as the difference between the group averages. The within-subject FC deviation
709 was computed by pooling the within-subject FC deviations of each subject, each of which
710 was obtained by subtracting the run-averaged FC from each run's FC data within a subject.
711 Subsequently, we calculated the WLS-FC variations by taking the standard deviation of
712 the WLS-FC deviations, which was obtained by projecting FC deviation vectors on the
713 biomarker space defined by the classifier weight parameters.

714

715 **Acknowledgments**

716 This study was supported by AMED (grant numbers: JP19dm0207069, JP18dm0307001,
717 JP18dm037002, JP18dm0307004, JP23dm0307008, JP23dm0307009,

718 JP21dm0207070h0003, JP21dm0307003h0004, and JP21dm0307004h0004), JST MS9
719 (grant number: JPMJMS2291), and JSPS KAKENHI (grant number: JP19H05726 and
720 23H00414).

721

722 **Author Contributions**

723 Conceptualization: OY and MK

724 Methodology: OY, AY, and YT

725 Investigation: OY, AY, YS, MK, TI, TY, SK, and GO

726 Visualization: OY

727 Funding acquisition: YO, KK, HT, MK, and OY

728 Data curation: AY, YS, YO, GO, MT, MN, TI, TH, YY, TM, TO, HT, HT, JN, HT, KH,
729 KK, NO, OA, HI, TY, SK, and SCT

730 Project administration: OY, YO, TH, KK, HI, TY, SK, SCT, and MK

731 Supervision: OY

732 Writing—original draft: OY and MK

733 Writing—review & editing: All authors

734

735 **Conflict of Interest**

736 TO received a research grant from Siemens Healthcare KK that was unrelated to the
737 submitted study.

738


739 **References**

- 740 1. Arias, D., Saxena, S. & Verguet, S. Quantifying the global burden of mental
741 disorders and their economic value. *EClinicalMedicine* **54**, (2022).
- 742 2. Abi-Dargham, A. *et al.* Candidate biomarkers in psychiatric disorders: state of
743 the field. *World Psychiatry* **22**, 236–262 (2023).
- 744 3. Fox, M. D. & Greicius, M. Clinical applications of resting state functional
745 connectivity. *Front Syst Neurosci* **4**, 1443 (2010).
- 746 4. Biswal, B., Yetkin, F. Z., Haughton, V. M. & Hyde, J. S. Functional connectivity
747 in the motor cortex of resting human brain using echo-planar MRI. *Magn Reson*
748 *Med* **34**, 537–41 (1995).
- 749 5. Fox, M. D. & Raichle, M. E. Spontaneous fluctuations in brain activity observed
750 with functional magnetic resonance imaging. *Nat Rev Neurosci* **8**, 700–11
751 (2007).
- 752 6. Finn, E. S. *et al.* Functional connectome fingerprinting: identifying individuals
753 using patterns of brain connectivity. *Nat Neurosci* **18**, 1664–71 (2015).


- 754 7. Smith, S. M. *et al.* A positive-negative mode of population covariation links
755 brain connectivity, demographics and behavior. *Nature Neuroscience* 2015
756 18:11 18, 1565–1567 (2015).
- 757 8. Liégeois, R. *et al.* Resting brain dynamics at different timescales capture distinct
758 aspects of human behavior. *Nat Commun* 10, (2019).
- 759 9. Dosenbach, N. U. F. *et al.* Prediction of individual brain maturity using fMRI.
760 *Science* 329, 1358–61 (2010).
- 761 10. Smith, S. M. *et al.* Correspondence of the brain’s functional architecture during
762 activation and rest. *Proc Natl Acad Sci U S A* 106, 13040–5 (2009).
- 763 11. Tavor, I. *et al.* Task-free MRI predicts individual differences in brain activity
764 during task performance. *Science (1979)* 352, 216–220 (2016).
- 765 12. Blautzik, J. *et al.* Classifying fMRI-derived resting-state connectivity patterns
766 according to their daily rhythmicity. *Neuroimage* 71, 298–306 (2013).
- 767 13. Honey, C. J. *et al.* Predicting human resting-state functional connectivity from
768 structural connectivity. *Proc Natl Acad Sci U S A* 106, 2035–40 (2009).
- 769 14. Shmuel, A. & Leopold, D. A. Neuronal correlates of spontaneous fluctuations
770 in fMRI signals in monkey visual cortex: Implications for functional connectivity
771 at rest. *Hum Brain Mapp* 29, 751–761 (2008).
- 772 15. Lake, E. M. R. *et al.* Simultaneous cortex-wide fluorescence Ca²⁺ imaging and
773 whole-brain fMRI. *Nature Methods* 2020 17:12 17, 1262–1271 (2020).
- 774 16. Ma, Z., Zhang, Q., Tu, W. & Zhang, N. Gaining insight into the neural basis of
775 resting-state fMRI signal. *Neuroimage* 250, 118960 (2022).
- 776 17. Yahata, N. *et al.* A small number of abnormal brain connections predicts adult
777 autism spectrum disorder. *Nat Commun* 7, 11254 (2016).
- 778 18. Itahashi, T. *et al.* Generalizable neuromarker for autism spectrum disorder
779 across imaging sites and developmental stages: A multi-site study. *bioRxiv* 11,
780 2023.03.26.534053 (2023).
- 781 19. Yamashita, A. *et al.* Generalizable brain network markers of major depressive
782 disorder across multiple imaging sites. *PLoS Biol* 18, e3000966 (2020).
- 783 20. Kawashima, T. *et al.* Generalisable functional imaging classifiers of
784 schizophrenia have multifunctionality as trait, state, and staging biomarkers.
785 *medRxiv* 2024.01.02.23300101 (2024) doi:10.1101/2024.01.02.23300101.
- 786 21. Drysdale, A. T. *et al.* Resting-state connectivity biomarkers define
787 neurophysiological subtypes of depression. *Nat Med* 23, 28–38 (2017).
- 788 22. Tokuda, T. *et al.* Identification of depression subtypes and relevant brain
789 regions using a data-driven approach. *Sci Rep* 8, (2018).

- 790 23. Watanabe, T., Sasaki, Y., Shibata, K. & Kawato, M. Advances in fMRI Real-
791 Time Neurofeedback. *Trends Cogn Sci* **21**, 997–1010 (2017).
- 792 24. Yamada, T. *et al.* Resting-State Functional Connectivity-Based Biomarkers and
793 Functional MRI-Based Neurofeedback for Psychiatric Disorders: A Challenge
794 for Developing Theranostic Biomarkers. *International Journal of*
795 *Neuropsychopharmacology* **20**, 769–781 (2017).
- 796 25. Yahata, N., Kasai, K. & Kawato, M. Computational neuroscience approach to
797 biomarkers and treatments for mental disorders. *Psychiatry Clin Neurosci* **71**,
798 215–237 (2017).
- 799 26. Cole, E. J. *et al.* Stanford Neuromodulation Therapy (SNT): A Double-Blind
800 Randomized Controlled Trial. *Am J Psychiatry* **179**, 132–141 (2022).
- 801 27. Winter, N. R. *et al.* A Systematic Evaluation of Machine Learning-Based
802 Biomarkers for Major Depressive Disorder. *JAMA Psychiatry* (2024).
- 803 28. Woo, C. W., Chang, L. J., Lindquist, M. A. & Wager, T. D. Building better
804 biomarkers: Brain models in translational neuroimaging. *Nat Neurosci* **20**, 365–
805 377 (2017).
- 806 29. Kohoutová, L. *et al.* Toward a unified framework for interpreting machine-
807 learning models in neuroimaging. *Nat Protoc* **15**, 1399–1435 (2020).
- 808 30. Yan, C. G. *et al.* Reduced default mode network functional connectivity in
809 patients with recurrent major depressive disorder. *Proc Natl Acad Sci U S A*
810 **116**, 9078–9083 (2019).
- 811 31. Dong, D., Wang, Y., Chang, X., Luo, C. & Yao, D. Dysfunction of Large-Scale
812 Brain Networks in Schizophrenia: A Meta-analysis of Resting-State Functional
813 Connectivity. *Schizophr Bull* **44**, 168–181 (2018).
- 814 32. Javaheripour, N. *et al.* Altered resting-state functional connectome in major
815 depressive disorder: a mega-analysis from the PsyMRI consortium. *Transl*
816 *Psychiatry* **11**, (2021).
- 817 33. Ilioska, I. *et al.* Connectome-wide Mega-analysis Reveals Robust Patterns of
818 Atypical Functional Connectivity in Autism. *Biol Psychiatry* **94**, 29–39 (2023).
- 819 34. Okada, G. *et al.* Verification of the brain network marker of major depressive
820 disorder: Test-retest reliability and anterograde generalization performance for
821 newly acquired data. *J Affect Disord* **326**, 262–266 (2023).
- 822 35. Noble, S. *et al.* Multisite reliability of MR-based functional connectivity.
823 *Neuroimage* **146**, 959–970 (2017).
- 824 36. Yamashita, A. *et al.* Harmonization of resting-state functional MRI data across
825 multiple imaging sites via the separation of site differences into sampling bias

- 826 and measurement bias. *PLoS Biol* **17**, e3000042 (2019).
- 827 37. Tanaka, S. C. *et al.* A multi-site, multi-disorder resting-state magnetic
828 resonance image database. *Scientific Data* **2021 8:18**, 1–15 (2021).
- 829 38. Koike, S. *et al.* Brain/MINDS beyond human brain MRI project: A protocol for
830 multi-level harmonization across brain disorders throughout the lifespan.
831 *Neuroimage Clin* **30**, (2021).
- 832 39. Kaiser, R. H., Andrews-Hanna, J. R., Wager, T. D. & Pizzagalli, D. A. Large-
833 Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of
834 Resting-State Functional Connectivity. *JAMA Psychiatry* **72**, 603–611 (2015).
- 835 40. Ichikawa, N. *et al.* Primary functional brain connections associated with
836 melancholic major depressive disorder and modulation by antidepressants. *Sci*
837 *Rep* **10**, 10 (2020).
- 838 41. Mueller, S. *et al.* Individual Variability in Functional Connectivity Architecture
839 of the Human Brain. *Neuron* **77**, 586–595 (2013).
- 840 42. Laumann, T. O. *et al.* Functional System and Areal Organization of a Highly
841 Sampled Individual Human Brain. *Neuron* **87**, 657–670 (2015).
- 842 43. Birn, R. M. *et al.* The effect of scan length on the reliability of resting-state
843 fMRI connectivity estimates. *Neuroimage* **83**, 550–8 (2013).
- 844 44. Glasser, M. F. *et al.* A multi-modal parcellation of human cerebral cortex.
845 *Nature* **2016 536:7615** **536**, 171–178 (2016).
- 846 45. Esteban, O. *et al.* fMRIPrep: a robust preprocessing pipeline for functional MRI.
847 *Nature Methods* **2018 16:1** **16**, 111–116 (2018).
- 848 46. Power, J. D. *et al.* Methods to detect, characterize, and remove motion artifact
849 in resting state fMRI. *Neuroimage* **84**, 320–41 (2014).
- 850 47. Penrose R. A generalized inverse for matrices. *Mathematical Proceedings of the*
851 *Cambridge Philosophical Society* **51**, 406–413 (1955).
- 852
- 853




858 **Figure 1. Schematic of the data analysis protocol used in this study.** Two traveling-subject datasets from two nationwide
859 projects conducted in Japan (Brain/Minds Beyond (BMB) and Strategic Research Program for Brain Sciences (SRPBS), along
860 with a multi-disorder dataset from SRPBS, were analyzed in the present study to facilitate a more comprehensive understanding
861 of functional connectivity (FC) variations related to individual differences, scanner differences, imaging protocol differences, and
862 unexplained residual components in comparison to disorder-related FC variations. First, we computed the FC variations due to
863 each factor and residual components using a carefully designed linear fixed effects model. We separately computed the within-
864 subject across-runs FC variations using a subset of the traveling-subject datasets (inclusion criteria: subjects with data from at
865 least six runs under a single measurement condition). The FC was characterized by the magnitude of the FC variations attributed
866 to differences in individuals (participants), scanners, imaging protocols, within-subject across-run differences, and disorder
867 differences. Furthermore, we evaluated the impact of each factor's FC variations on the outcomes of the multivariate FC
868 biomarker we previously developed using least absolute shrinkage and selection operator (LASSO) ensemble classifiers¹⁹.
869



870
871
872
873
874
875
876
877

Figure 2. Analysis of functional connectivity (FC) variations for the Brains/Minds Beyond (BMB) traveling-subject dataset based on Glasser’s Multimodal Parcellation (MMP) atlas. A linear fixed effects model with three factors was applied to the BMB traveling-subject dataset to investigate the FC variations due to the participant (73 subjects), imaging protocol (three protocols), and scanner (six scanners) factors, and the unmodeled residual component, which was characterized on the basis of separately computed within-subject FC variations. (a) Distributions of the magnitudes of the FC variations due to the participant, scanner, protocol, residual component, and within-subject factors. Each violin plot summarizes the whole-brain FC variations

878 across 71,631 connections. The median value of each distribution is shown above each violin plot. (b) Comparison of the
879 connectivity pattern similarity between the residual component and within-subject variations. Each dot corresponds to one
880 connectivity. (c) Brain mapping of the FC variations due to the participant, within-subject, residual, scanner, and imaging protocol
881 factors. (d) Brain networks of the FC variations summarized using Yeo's 7-network parcellation. All reported values are
882 represented by Fisher's z-transformed Pearson correlation coefficients.
883



885

886

887

888

889


890

891

892

Figure 3. Analysis of functional connectivity (FC) variations for the Strategic Research Program for Brain Sciences (SRPBS) traveling-subject dataset based on Glasser's Multimodal Parcellation (MMP) atlas. A linear fixed effects model with two factors was applied to the SRPBS traveling-subject dataset to investigate the FC variations due to the participant (nine subjects) and scanner (seven scanners) factors and the unmodeled residual component. The unmodeled residual component was characterized by separately computed within-subject FC variations. (a) The distributions of the magnitudes of the FC variations due to the participant, scanner, residual component, and within-subject factors. Each violin plot summarizes the whole-brain FC variations across 71,631 connections. The median value of each distribution is shown above each violin plot. (b) Comparison of

893 the connectivity pattern similarity between the residual component and within-subject variations. Each dot corresponds to one
894 connectivity. (c) Brain mapping of the FC variations due to the participant, within-subject, residual, and scanner factors. (d) Brain
895 networks of the FC variations summarized using Yeo's 7-network parcellation. All reported values are represented by Fisher's z-
896 transformed Pearson correlation coefficients.
897



898

899

900

901

902

903

904

905


906

907

908

Figure 4. Comparison of the disorder-related functional connectivity (FC) differences between groups of patients with major depressive disorder (MDD), autism spectrum disorder (ASD), or schizophrenia (SCZ) and age- and-sex-matched healthy controls. (a) Distributions of the magnitudes of the disorder-related FC differences. (b) Brain mapping of the disorder-related FC differences (c). Brain networks of the FC differences summarized using Yeo's 7-network parcellation. (d) The 50 largest FC variations summarized using Yeo's 7-network parcellation. All reported values represent Fisher's z-transformed Pearson correlation coefficients.


909



910

911 **Figure 5. Analysis of the effects of functional connectivity (FC) variations on the**
912 **multivariate connectivity biomarker outputs.** We evaluated the impact of FC variations
913 due to the participant, imaging protocol, scanner, within-subject, and disorder factors on
914 the outputs of major depressive disorder (MDD), autism spectrum disorder (ASD), and
915 schizophrenia (SCZ) biomarkers developed in our previous study¹⁹. The biomarker for
916 each psychiatric disorder consisted of an ensemble of 100 linear classifiers, each of which
917 was trained with partially overlapping but distinct subsampled data using the least
918 absolute shrinkage and selection operator (LASSO) algorithm. The output of each
919 classifier was a scalar value that represented the weighted linear summation of the FC
920 (WLS-FC). The final decision value, indicating the likelihood of the presence of the
921 disorder, was obtained by averaging the outputs of all 100 classifiers. (a) The distributions
922 of the magnitudes of the FC variations of 50 LASSO-selected connections (left-half
923 histogram) and the top 50 MDD-related connections (right half histogram, for the
924 connections displayed in Fig. 4(d)) superimposed on the magnitude distributions of all
925 71,631 FCs (violin plots, integrated with Fig 2(a) and 4(a)). The asterisk and ns. indicate
926 statistical significance and non-significance ($p < 0.001$) from two-sample Kolmogorov-

927 Smirnov test, respectively. (b)(c) The same data analyses are shown for the ASD and SCZ
928 biomarkers. (d) The impact of the FC variations on the output of the MDD biomarker.
929 The unfilled bars represent the variation of each classifier output averaged across all 100
930 classifiers (the error bar indicates the standard deviation), whereas the filled bars represent
931 the variation of the final decision value. (e)(f) The same analyses are shown for the ASD
932 and SCZ biomarkers, respectively.
933
934



935

936

937 **Figure 6. Signal-to-noise ratio (SNR) estimates of the FCs and the LASSO**
938 **classifier outputs for MDD, ASD and SCZ.** For each individual FC or classifier
939 output, the SNR was defined as the disorder-related variation divided by summation of
940 the participants, within-subject, scanner and imaging protocol variations. ‘All FCs’
941 represents the SNR distribution of the individual FCs collecting from all 71631 FCs.
942 ‘Top 50 disorder-related FCs’ represents average SNR of the 50 individual FCs with the
943 largest MDD-related variation. ‘Top 50 LASSO-selected FCs’ represents average SNR
944 of the 50 individual FCs which was most frequently selected by the LASSO classifiers.
945 ‘Single classifier outputs’ and ‘Ensemble averaged output’ represent the SNRs of the
946 LASSO classifier outputs before and after ensemble average, respectively. (a)(b)(c) the
947 SNR estimates of MDD, ASD and SCZ, respectively. The SNR values are listed in the
948 supplementary table 1.

949